Torrent Pharmaceuticals vs Aurobindo Pharma: Which Stock Should You Track

Torrent Pharmaceuticals vs Aurobindo Pharma is a comparison mid-to-large pharma investors look up when evaluating two listed Indian pharmaceutical companies with different business models. Torrent Pharmaceuticals is an Ahmedabad-based branded pharma company with a strong domestic chronic therapy franchise and a growing US generics business, while Aurobindo Pharma is a large generic pharma company focused on US generics and European markets with a broad injectable and oral solid dose portfolio.

This Torrent Pharmaceuticals vs Aurobindo Pharma article covers reach and market position, key products, latest declared results and stock valuation. The Torrent Pharmaceuticals vs Aurobindo Pharma data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Torrent Pharmaceuticals vs Aurobindo Pharma: Reach and Market Position

On the Torrent Pharmaceuticals side of the Torrent Pharmaceuticals vs Aurobindo Pharma comparison, Torrent Pharmaceuticals is among the top Indian pharma companies by domestic branded prescription. It also sells in the US through its subsidiary Torrent Pharma US and has Europe presence through Heumann Pharma. Market capitalisation is Rs 1,90,108 Cr.

Click Here – Get Free Investment Predictions

On the Aurobindo Pharma side of the Torrent Pharmaceuticals vs Aurobindo Pharma comparison, Aurobindo Pharma is one of India's largest pharma exporters with a primary focus on the US generics market. It also sells in Europe, emerging markets and has a significant injectables business. Market capitalisation is Rs 93,707 Cr.

Torrent Pharmaceuticals vs Aurobindo Pharma: Key Products and Business Mix

In the Torrent Pharmaceuticals vs Aurobindo Pharma product comparison, Torrent Pharmaceuticals offers: Torrent earns from India branded chronic therapies (cardiovascular, CNS, gastro, diabetology), US generics and European market. EPS is Rs 56.68. P/E is 88.18x, ROE 25.49 percent, D/E 1.79.

For Aurobindo Pharma in this Torrent Pharmaceuticals vs Aurobindo Pharma breakdown: Aurobindo earns from oral solid doses, injectables, dermatology, oncology and ARV for US and European generics markets. EPS is Rs 60.31. P/E is 26.75x, ROE 9.25 percent, D/E 0.21.

Torrent Pharmaceuticals vs Aurobindo Pharma: Latest Results

The Torrent Pharmaceuticals vs Aurobindo Pharma results for Torrent Pharmaceuticals: Torrent Pharmaceuticals has a market cap of Rs 1,90,108 Cr and P/E of 88.18x. ROE is 25.49 percent — significantly above most Indian pharma peers. D/E of 1.79 reflects acquisition-led growth (Unichem acquisition).

The Torrent Pharmaceuticals vs Aurobindo Pharma results for Aurobindo Pharma: Aurobindo Pharma has a market cap of Rs 93,707 Cr and P/E of 26.75x. ROE is 9.25 percent and D/E is 0.21. Aurobindo trades at a much lower P/E than Torrent, partially reflecting its lower ROE and commoditised US generics exposure.

Compare Torrent Pharmaceuticals and Aurobindo Pharma Fundamentals on the Univest Screener

Torrent Pharmaceuticals vs Aurobindo Pharma: Stock and Valuation

The Torrent Pharmaceuticals vs Aurobindo Pharma stock comparison uses the latest available market data from Groww. Investors tracking Torrent Pharmaceuticals vs Aurobindo Pharma should verify current prices on NSE or BSE before trading.

Torrent Pharmaceuticals vs Aurobindo Pharma at current valuations: Torrent trades at Rs 1,90,108 Cr market cap, P/E 88.18x, ROE 25.49 percent, D/E 1.79. Aurobindo trades at Rs 93,707 Cr market cap, P/E 26.75x, ROE 9.25 percent, D/E 0.21. Torrent is 2 times larger by market cap and trades at a much higher P/E reflecting its branded domestic franchise premium.

Torrent Pharmaceuticals vs Aurobindo Pharma: Quick Comparison Table

The Torrent Pharmaceuticals vs Aurobindo Pharma comparison table below summarises the key metrics covered in this article side by side.

Parameter	Torrent Pharmaceuticals	Aurobindo Pharma
Sector	Branded India + US generics	US generics export (oral + injectables)
Market Cap	Rs 1,90,108 Cr	Rs 93,707 Cr
P/E Ratio	88.18x	26.75x
ROE	25.49%	9.25%
Debt to Equity	1.79 (post Unichem acquisition)	0.21
India Business	Strong: cardiovascular, CNS, diabetology	Limited domestic branded presence
Dividend	0.68% yield	0.25% yield

Conclusion

The Torrent Pharmaceuticals vs Aurobindo Pharma comparison above covers the key data points on reach, products, results and valuation. Torrent Pharmaceuticals vs Aurobindo Pharma presents two fundamentally different pharma business models. Torrent has a high-quality branded domestic business with steady chronic prescriptions, while Aurobindo is a volume-driven US generic exporter with high competition. Both have US businesses but at different margin profiles. Investors should review US filing pipeline, USFDA inspection status, domestic market growth and branded vs generic revenue mix before taking a view. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track Torrent Pharmaceuticals and Aurobindo Pharma live price and get daily stock recommendations.

SEBI Research Analyst Registration No. INH000013776

Frequently Asked Questions

What therapies is Torrent Pharmaceuticals strong in?

Ans. Torrent is strong in chronic therapies — cardiovascular, CNS (central nervous system), gastrointestinal and diabetology. It has a large field force promoting branded generics to doctors in India.

What is Aurobindo Pharma known for?

Ans. Aurobindo is known for large-scale US generic exports in oral solid doses, injectables, dermatology and oncology. It has one of the highest numbers of ANDA (Abbreviated New Drug Application) filings among Indian pharma companies.

Why does Torrent have a higher P/E than Aurobindo?

Ans. Torrent commands a premium P/E due to its domestic branded franchise with steady ROE of 25 percent-plus. Aurobindo is a commodity generic exporter with lower and more volatile margins.

Does Torrent Pharmaceuticals pay dividends?

Ans. Yes. Torrent pays a dividend yield of approximately 0.68 percent.

What is ANDA filing in pharma?

Ans. ANDA stands for Abbreviated New Drug Application — the FDA submission for approval to market a generic version of a US-approved drug. A larger ANDA portfolio implies more US generic opportunities.

Is Aurobindo Pharma in Nifty 50?

Ans. Aurobindo Pharma is not in Nifty 50. Torrent Pharmaceuticals is not in Nifty 50 either. Both are tracked in the Nifty Pharma index.

Which is larger by market cap, Torrent or Aurobindo?

Ans. Torrent Pharmaceuticals is larger at Rs 1,90,108 Cr versus Aurobindo at Rs 93,707 Cr.